Dynamics of multiple myeloma tumor therapy with a recombinant measles virus

Cancer Gene Therapy

Volumn 16, Issue 12, 2009, Pages 873-882

  Dingli, D ^a   Offord, C ^b   Myers, R ^a   Peng, K W ^a   Carr, T W ^c   Josic, K ^d   Russell, S J ^a   Bajzer, Z ^b  

^a MAYO CLINIC ROCHESTER   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c SOUTHERN METHODIST UNIVERSITY   (United States)

^d University of Houston   (United States)

Author keywords

Mathematical modeling; Population dynamics; Tumor therapy; Viruses

Indexed keywords

ONCOLYTIC PARAMYXOVIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MEASLES VIRUS; MICROBIAL POPULATION DYNAMICS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SIMULATION; TUMOR XENOGRAFT; VIRUS RECOMBINANT;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; MEASLES VACCINE; MICE; MICE, SCID; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MULTIPLE MYELOMA; ONCOLYTIC VIROTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MEASLES VIRUS; REPLICATION COMPETENT VIRUSES;

EID: 70449637667     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.40     Document Type: Article

References (38)

1. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-6079.
2. Lorence RM, Roberts MS, O'Neil JD, Groene WS, Miller JA, Mueller SN et al. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 2007; 7: 157-167.
3. Reid V, Yu Z, Schuman T, Li S, Singh P, Fong Y et al. Herpes oncolytic therapy of salivary gland carcinomas. Int J Cancer 2008; 122: 202-208.
4. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
5. Dingli D, Cascino MD, Josic K, Russell SJ, Bajzer Z. Mathematical modeling of cancer radiovirotherapy. Math Biosci 2006; 199: 55-78.
6. Friedman A, Tian JP, Fulci G, Chiocca EA, Wang J. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res 2006; 66: 2314-2319.
7. Wein LM, Wu JT, Ianculescu AG, Puri RK. A mathematical model of the impact of infused targeted cytotoxic agents on brain tumours: implications for detection, design and delivery. Cell Prolif 2002; 35: 343-361.
8. Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 2003; 63: 1317-1324.
9. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res 2001; 61: 3501-3507.
10. Wodarz D. Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. Hum Gene Ther 2003; 14: 153-159.
11. Wu JT, Byrne HM, Kirn DH, Wein LM. Modeling and analysis of a virus that replicates selectively in tumor cells. Bull Math Biol 2001; 63: 731-768.
12. Wu JT, Kirn DH, Wein LM. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bull Math Biol 2004; 66: 605-625.
13. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001; 97: 3746-3754.
14. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001; 98: 2002-2007.
15. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656-4662.
16. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multi-forme. Cancer Res 2003; 63: 2462-2469.
17. McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM et al. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 2006; 99: 177-184.
18. Hadac EM, Peng KW, Nakamura T, Russell SJ. Reengineering paramyxovirus tropism. Virology 2004; 329: 217-225.
19. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23: 209-214.
20. Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R et al. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther 2001; 12: 811-821.
21. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002; 8: 527-531.
22. Dingli D, Kemp BJ, O'Connor MK, Morris JC, Russell SJ, Lowe VJ. Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. Mol Imaging Biol 2006; 8: 16-23.
23. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
24. Peng KW, Hadac EM, Anderson BD, Myers R, Harvey M, Greiner SM et al. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther 2006; 13: 732-738.
25. Bajzer Z, Carr T, Josic K, Russell SJ, Dingli D. Modeling of cancer virotherapy with recombinant measles viruses. J Theor Biol 2008; 252: 109-122.
26. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007; 82: 700-710.
27. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996; 10: 866-876.
28. Spratt JA, von Fournier D, Spratt JS, Weber EE. Decelerating growth and human breast cancer. Cancer 1993; 71: 2013-2019.
29. Bajzer Z. Gompertzian growth as a self-similar and allometric process. Growth Dev Aging 1999; 63: 3-11.
30. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716-723.
31. SCIENTIST, Micromath Scientific Software. Salt Lake City, Utah, 1995.
32. Offord C, Bajzer Z. A hybrid global optimization algorithm involving simplex and inductive search. Lect Notes Comput Sci 2006; 2074: 680-688.
33. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002; 9: 961-966.
34. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci 2007; 28: 326-333.
35. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004; 64: 4919-4926.
36. Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ et al. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 2006; 34: 713-720.
37. Dingli D, Peng KW, Harvey ME, Vongpunsawad S, Bergert ER, Kyle RA et al. Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun 2005; 337: 22-29.
38. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563-579